- Trials with a EudraCT protocol (44,400)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)
44,400 result(s) found.
Displaying page 1,285 of 2,220.
| EudraCT Number: 2014-002541-22 | Sponsor Protocol Number: EFC14092 | Start Date*: 2015-04-02 | |||||||||||
| Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
| Full Title: A randomized, double-blind, parallel-group study assessing the efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis | |||||||||||||
| Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) CZ (Completed) HU (Completed) ES (Completed) GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-000196-27 | Sponsor Protocol Number: 9744 | Start Date*: 2015-07-28 | |||||||||||
| Sponsor Name:QMUL and Bart's Health NHS trust | |||||||||||||
| Full Title: Tendinopathy treatment effects and mechanisms 1 (TEAM 1): A randomised clinical trial of eccentric loading, high volume injection and shock wave therapy for Achilles tendinopathy. | |||||||||||||
| Medical condition: Achilles tendinopathy | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-013037-19 | Sponsor Protocol Number: VB-201-006-A | Start Date*: 2010-02-08 | |||||||||||
| Sponsor Name:Vascular Biogenics Ltd. | |||||||||||||
| Full Title: A Randomized, Double-Blind, 12-Week, Dose-Ranging Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients with Moderate to Severe Plaque Psoriasis | |||||||||||||
| Medical condition: Moderate to Severe Plaque Psoriasis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-002529-48 | Sponsor Protocol Number: WADA2018vil | Start Date*: 2018-09-12 | |||||||||||
| Sponsor Name:Center for Aktiv Sundhed, Rigshospitalet | |||||||||||||
| Full Title: Urine concentrations of vilanterol after inhaled administration of vilanterol/fluticasone furoate: Defining a urine threshold and decision limit for vilanterol in doping control analysis | |||||||||||||
| Medical condition: Pharmacokinetics of vilanterol in relation to doping analysis | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-005518-44 | Sponsor Protocol Number: 15-01/GentaBet-C | Start Date*: 2015-10-27 | |||||||||||
| Sponsor Name:Dermapharm AG | |||||||||||||
| Full Title: Double-blind, randomised clinical study comparing efficacy and safety of Gentamicin 0.1%_Betamethasone 0.05% Cream (Test) vs. Diprogenta(R) Cream (Reference) vs. Vehicle in patients with bacterial ... | |||||||||||||
| Medical condition: Bacterial infected eczemas | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2016-004082-39 | Sponsor Protocol Number: GOOD-IDES-01 | Start Date*: 2017-01-23 | |||||||||||
| Sponsor Name:Linköping University | |||||||||||||
| Full Title: An Open-Label Phase II Study in anti-GBM disease (Goodpasture’s disease) with Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS --GOOD-IDES | |||||||||||||
| Medical condition: Anti-GBM disease (Goodpasture’s disease) with Adverse Renal Prognosis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) DK (Completed) AT (Completed) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-004675-22 | Sponsor Protocol Number: ADM-PED08 | Start Date*: 2008-10-21 | |||||||||||
| Sponsor Name:University of Bonn | |||||||||||||
| Full Title: Intravitreal ranibizumab in patients with retinal pigment epithelial detachments secondary to AMD | |||||||||||||
| Medical condition: Pigment epithelial detachments secondary to age-relatedmacular degeneration | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2011-003218-17 | Sponsor Protocol Number: TRANEX1 | Start Date*: 2012-11-08 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Hospital Universitario La Paz | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Efficacy of topical tranexamic acid versus intravenous administration to reduce blood transfussion rate in total knee arthroplasty surgery: phase III, unicentric, controlled,double blind, randomiz... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: El sangrado perioperatorio es común en intervenciones quirúrgicas de ortopedia, especialmente en los reemplazos de rodilla con una estimación media de transfusión de concentrados de hematíes de un... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2014-003010-93 | Sponsor Protocol Number: 620 | Start Date*: 2014-10-15 |
| Sponsor Name:Sint Maartenskliniek | ||
| Full Title: Pharmacokinetic Profile of Ropivacaïne after Periarticular Local Infiltration Analgesia for Primary Total Knee Arthroplasty | ||
| Medical condition: patients receiving primary total knee replacement | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2020-003284-25 | Sponsor Protocol Number: CKAF156A2202 | Start Date*: 2021-02-18 | ||||||||||||||||
| Sponsor Name:Novartis Pharma AG | ||||||||||||||||||
| Full Title: A Phase 2 interventional, multicenter, randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersion Formulation in combination, given once d... | ||||||||||||||||||
| Medical condition: Uncomplicated Plasmodium falciparum malaria | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: Outside EU/EEA | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2010-023139-40 | Sponsor Protocol Number: CD-2010-01 | Start Date*: 2012-10-29 |
| Sponsor Name:Instituto Científico y Tecnológico de Navarra | ||
| Full Title: Estudio fase II con inmunoterapia mediante células dendríticas e Hiltonol en pacientes con tumores sólidos. | ||
| Medical condition: Tumores sólidos avanzados, no susceptibles de tratamiento convencional. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-002821-31 | Sponsor Protocol Number: AKST4290-206 | Start Date*: 2019-10-10 | |||||||||||
| Sponsor Name:Alkahest, Inc | |||||||||||||
| Full Title: The Effect of AKST4290 on Choroidal Blood Flow in Patients with Neovascular Age-Related Macular Degeneration | |||||||||||||
| Medical condition: Age-related macular degeneration | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-024131-16 | Sponsor Protocol Number: UKM10_0019 | Start Date*: 2011-05-06 | |||||||||||
| Sponsor Name:Universitätsklinikum Münster | |||||||||||||
| Full Title: Efficacy and Safety of oral Alitretinoin (Toctino®) in the Treatment of Patients with Cutaneous Lupus Erythematosus: A Multicentre, Open-Label, Prospective Pilot Study | |||||||||||||
| Medical condition: Αdult subjects of any ethnicity and either gender with Subacute Cutaneous Lupus Erythematosus (SCLE), Discoid Lupus Erythematosus (DLE), Lupus erythematosus tumidus (LET) or Systemic Lupus Erythema... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-004150-85 | Sponsor Protocol Number: HINEF: PDE5 | Start Date*: 2008-04-11 |
| Sponsor Name:Charité Universitaetsmedizin Berlin | ||
| Full Title: Cardiac failure with normal ejection fraction: possible role of phosphodiesterase type 5 inhibitors | ||
| Medical condition: Patients with cradiac failure and normal ejection fraction | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-003203-35 | Sponsor Protocol Number: VP-C21-004 | Start Date*: 2019-12-13 | ||||||||||||||||
| Sponsor Name:Vicore Pharma AB | ||||||||||||||||||
| Full Title: A Phase 2, single-center, randomised, double-blind, placebo-controlled, cross-over, cold challenge study investigating the effect of C21 on cold-induced vasoconstriction in subjects with Raynaud’s ... | ||||||||||||||||||
| Medical condition: Systemic sclerosis (SSc) Raynaud’s phenomenon (RP) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2018-001125-15 | Sponsor Protocol Number: ATB-202 | Start Date*: 2018-07-16 | |||||||||||||||||||||
| Sponsor Name:Atox Bio | |||||||||||||||||||||||
| Full Title: Phase III, randomized, double-blind, placebo controlled, parallel-group, study of AB103 as compared to placebo in patients with necrotizing soft tissue infections (NSTI) | |||||||||||||||||||||||
| Medical condition: Necrosis of soft tissue infections (NSTI) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: FR (Completed) | |||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||
| EudraCT Number: 2006-004799-11 | Sponsor Protocol Number: 2006OB01 | Start Date*: 2007-11-29 |
| Sponsor Name:Coombe Women's Hospital | ||
| Full Title: A randomised trial of oxytocin bolus versus oxytocin bolus and infusion for the control of blood loss at elective caesarean section. | ||
| Medical condition: Elective lower segment caesarean section | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: IE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-002038-35 | Sponsor Protocol Number: S62619 | Start Date*: 2019-06-27 | |||||||||||
| Sponsor Name:UZ Leuven | |||||||||||||
| Full Title: A prospective study investigating ustekinumab concentrations through dried blood spot sampling in Crohn’s disease patients | |||||||||||||
| Medical condition: Crohn's disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-001985-25 | Sponsor Protocol Number: 250-201 | Start Date*: 2015-11-06 | ||||||||||||||||
| Sponsor Name:Allievex Corporation | ||||||||||||||||||
| Full Title: A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular AX 250 in Patients with Mucopolysaccharidosis Type IIIB ... | ||||||||||||||||||
| Medical condition: Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B, MPS IIIB) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Completed) DE (Completed) ES (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2016-004176-22 | Sponsor Protocol Number: IMPURE-Study | Start Date*: 2017-04-28 |
| Sponsor Name:Medizinische Universität Graz | ||
| Full Title: IMProving Ultrafiltration and REmoval of uremic toxins by adapted automated peritoneal dialysis in a single center study (IMPURE-Study). | ||
| Medical condition: Chronic kidney disease G5D | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.